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Abstract    
Testosterone (T) can alter sexual, social, anxiety-like, and/or cognitive behavior of male 
rodents and exert trophic effects on the prostate.  However, whether these effects are due 
to actions of T, or its 5-reduced and/or aromatized metabolites, is of interest.  We tested 
the hypothesis that T’s effects to enhance prostate proliferation, sexual, social, cognitive 
and/or anti-anxiety-like behavior require formation of 5-reduced and/or aromatized 
metabolites. Gonadectomized (GDX) or gonadally-intact rats were administered T-
containing, or empty, silastic capsules in conjunction with a 5-reductase inhibitor 
(finasteride; Experiment 1) or an aromatase inhibitor (formestane; Experiment 2). The 
performance of rats in sexual, cognitive (object recognition, object placement, water 
maze), anxiety-like (open field, elevated plus maze, light–dark transition, mirror maze, 
social interaction) tasks were examined.  Prostate mass and concentrations of T and its 
metabolites were assessed.  Rats that were GDX, compared to intact rats, had lower 
androgen levels, smaller prostates, longer latencies to initiate sexual contacts, had poorer 
cognitive performance in the object placement and water maze tasks, and demonstrated 
more anxiety-like behavior in the light/dark transition task and the mirror maze.  
Finasteride produced effects similar to GDX to decrease prostate weight and inhibit 
sexual behavior and spatial cognition, but not affective behaviors.  Formestane did not 
alter prostate mass or sexual behavior, but did enhance cognitive performance in the 
object recognition task and tended to increase central entries in the open field, an 
indication of anti-anxiety behavior.  Thus, shunting T’s metabolism from aromatization 
to favor 5-reduction had beneficial cognitive and anti-anxiety effects without negative 
effects on prostate or sexual behavior. 
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Introduction 
Aging men can experience decline in gonadal, sexual, cognitive, and affective 
function. For men, androgen levels begin to rise after puberty and remain high until 
midlife (Hiort, 2002), when a decade-by-decade decline in endogenous androgen levels 
occurs (Morley et al,. 1997). On average, this decline, involves a 0.4% reduction in total 
testosterone and a 1.2% reduction in biologically-free testosterone per year, causing mean 
total plasma testosterone levels decrease by about 35% between 25 and 75 years of age 
(Schatzl et al., 2003; Vermeulen, 2000).  Some behavioral sequelae associated with aging 
include poorer performance in spatial tasks, greater anxiety and depression, and 
decreased sexual motivation (Davidson Kwan and Greenleaf, 1982; Basaria & Dobs, 
2001; 2002; Morley et al., 2001; Janowsky Oviatt and Orwoll, 1994; Seidman, 2002). In 
addition to androgen-sensitive changes in behavior, there are physical changes, such as 
increased risk for benign prostate hyperplasia (BPH) and prostate cancer (Untergasser, 
Rumpold, Hermann, Dirnhofer, Jilg and Berger, 1999).  These physical changes worsen 
with aging, as frequency of moderate and worse urinary symptoms related to BPH rise 
from 13% in the fifth to 28% in the eighth decade of life (Kaplan, 2005).  Affective, 
cognitive, and physical decline associated with aging is of particular importance given 
that demographics suggest that older age groups are increasing as a percentage of the 
population (Nieschlag et al., 2006).  Many men seek testosterone (T) replacement therapy 
(TRT) to combat these effects (Marks & Kaplan 2009; Kaufman & Seftel, 2004). TRTs 
have successfully been used to improve spatial cognition, libido and depression (Tenover, 
1998; Janowsky, Oviatt, and Orwoll, 1994; Pope, Cohane, Kanayama, Siegel, and 
Hudson, 2003).  However, TRTs are also associated with negative consequences 
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including increased risk for prostate cancer (Raynaud, 2006). Greater understanding is 
needed of the relative trophic effects of androgens on peripheral and central tissues. 
In rodent models, decline in endogenous T can produce negative effects on 
sexual, cognitive, and anxiety-like, behavior. Older male rodents demonstrate similar 
behavioral decline to that of aging men: aged rodents display decreased sexual motivation 
and cognitive performance in spatial tasks (Chambers, Thornton, Roselli, 1991; Spruijt 
Meyerson, and Hodlund, 1989; Barnes, 1988).  Extirpation of the testes, a primary source 
of androgens, can reduce plasma levels of androgens (Krey & McGinnis, 1990).  Separate 
studies have shown that gonadectomy (GDX) of rodents produces behavioral effects 
similar to those seen with aging, including decreased sexual proceptivity, cognition, 
increased anxiety and depressive behavior (Adler, Vescovo, Robinson, and Kritzer, 1999; 
Hull & Dominguez, 2007; Aubele, Kaufman, Montalmant and Kritzer, 2008; Bernardi 
Genedani, Tagliavini, and Bertolini, 1989).  Akin to hormone replacement therapy, 
administering T to rats reinstates sexual, cognitive, and affective, performance 
commensurate to that of gonadally-intact rats (Delhez, Hansenne, and Legros, 2003; 
Kritzer, Brewer, Montalman, Davenport, and Robinson, 2007), but coincident effects of 
prostate proliferation are of interest.  Thus, utilizing a GDX model is useful for 
determining the effects of decreasing androgen levels with aging.   
  Some of T’s psychological and physiological effects may be mediated, in part, 
through actions of its 5-reduced and/or aromatized metabolites.  Testosterone is 
metabolized by 5α-reductase enzymes to form 5α-dihydrotestosterone (DHT; Handa, 
Pak, Kudwa, Lund, and Hinds, 2008).  In addition, T is metabolized by aromatase to form 
estradiol (E2: Alejandre-Gomez, Garcia-Segura, Gonzalez-Burgos., 2007; Ellem & 
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Risbridger, 2009; Lephart Lund and Horvath, 2001; Séralini & Moslemi, 2001). 
Interestingly, among rats, levels of T and its 5-reduced metabolites decline with aging 
(Frye et al., 2010).  However, with aging among men, E2 levels remain unchanged or 
increase, resulting in a decrease in the ratio of T to E2 (Ellem & Risbridger; Vermeulen, 
2000).  Thus, the ratio of T to its 5-reduced and/or aromatized metabolites in relation to 
effects on prostate and behavior is of interest.   
 The testes are a significant source of androgens, but T, its 5-reduced, and 
aromatized metabolites, are also produced in the brain.  Trophic effects of T in the brain 
may be in part dependant, and independent of, gonadal condition.  For example, GDX 
reduces the number of aromatase-positive neurons in the hypothalamus, but not limbic 
areas (Jakab, Horvath, Leranth, Harada, and Naftolin, 1993).  Within limbic regions, such 
as the hippocampus, androgen-mediated spine synapse density can be in part independent 
of systemic androgenic potency (MacLusky, Hajszan, Prange-Kiel, and Leranth, 2006).   
Interestingly, androgen-induced remodeling of spine synapses in the hippocampus and 
prefrontal cortex occur independently, and dependently, respectively of actions at 
androgen receptors (ARs; Hajszan, Milner, and Leranth, 2007).   Thus, androgens can 
exert diverse effects and mechanisms for its trophic actions in the brain. 
   We investigated the relationship between T and its metabolites on reproductive, 
cognitive, and affective behavior as well as their proliferative effects in the prostate in 
two experiments. Rats were gonadally-intact, or GDX and implanted with silastic 
capsules that were empty or contained T.  In Experiment 1, rats also had silastic capsules 
containing a 5-reductase inhibitor, finasteride or control implants.  In Experiment 2, rats 
received silastic capsules containing an aromatase inhibitor, formestane, or control 
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implants.  All rats were tested for reproductive, cognitive, and affective behavior, in a 7 
week-long battery. At the end of the battery, prostate was collected and wet weight was 
obtained as an indication of mass. Plasma and brains were collected for measurement of 
peripheral and central androgen concentrations.  We anticipated that GDX and finasteride 
would decrease, while T and formestane would increase, sexual motivation, performance 
in cognitive tasks, anti-anxiety-like behavior, and prostate weights in correlation with 
formation of T’s metabolites.  
Materials and Methods 
These methods were pre-approved by the Institutional Animal Care and Use 
Committee at the University at Albany- SUNY. 
Animals & Housing 
Male Long-Evans rats (N=250), approximately 2 months old at the start of the 
experiment, were obtained from our in-house breeding colony (original stock from 
Charles River Laboratories, Raleigh, NC). Rats were group-housed (3-4 per cage) in 
polycarbonate cages (45 X 24 X 21 cm) in the Laboratory Animal Care Facility of The 
Life Sciences Research Building at The University at Albany-SUNY.  Subjects were 
housed in a temperature- (21 ± 1 °C) and humidity- (50 ± 5%) controlled room that was 
maintained on a 12:12 h reversed light cycle (lights off at 0800 h). Throughout the 
investigation, rats had continuous access to Purina Rat Chow and tap water in their home-
cages. 
Surgery: Gonadectomy and Implantation 
 Rats were either GDX or sham-surgerized under xylazine (12 mg/kg; Bayer 
Corp., Shawnee Mission, KS) and ketamine (60 mg/kg; Fort Dodge Animal Health, Fort 
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Dodge, IA) anesthesia, 26-30 days before the start of behavioral testing.  At the time of 
GDX or sham surgery, rats were randomly assigned to receive a silastic implant (1.57 
mm inner diameter, 3.18 mm outer diameter; 10mm/rat) that was empty (vehicle), 
contained crystalline T, and/or one silastic that contained finasteride (Experiment 1) or 
formestane (Experiment 2) as modified from previous methods (Frye, Edinger, Seliga, 
Wawrzycki, 2004).  Following surgery, and prior to testing, all rats were monitored for 
neurological status by monitoring for loss of weight, righting response, flank stimulation 
response, and/or muscle tone (Marshall & Teitelbaum, 1974).  One rat (GDX with 
finasteride) did not pass these assessments and was immediately euthanized. 
Behavioral Testing  
Rats were tested in two tasks per week with a minimum of 2 days between tests. 
Behavioral data were collected by one trained, blinded, observer (DJD), using a video-
tracking system (ANY-Maze- Stoelting, Inc., Wood Dale, IL).  Unless otherwise 
indicated, testing was conducted in an open field (76 x 57 x 35 cm), situated in a brightly-
lit room. 
Sexual Behavior: Rats were tested for sexual behavior in a chamber (37.5 x 75 x 30 cm), 
per previously reported methods (Edinger & Frye, 2007). Briefly, each rat was placed in 
the chamber with a sexually-receptive female (ovariectomized rat administered 
supraphysiological levels of E2) for 10 mins. Latencies to, and frequencies of mounts, 
intromissions and ejaculations were recorded.  No significant differences were observed 
in mounting or ejaculatory behavior.  Latencies to initial intromission are indicative of 
sexual capacity.  
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Social Interaction: Testing was conducted per previously reported methods (Frye Petralia 
and Rhodes, 2000). Rats were placed in the chamber with a novel male conspecific.  
Amount of time in social interaction (sniffing, grooming, crawling over/under, following 
with contact, engaging in rough and tumble interaction) was recorded. Time spent 
interacting is an index of social/affective behavior.   
Object Recognition:  This procedure was implemented as per prior methods (Ennaceur & 
Delacour 1988; Frye & Lacey, 2001; Paris & Frye, 2008; Luine, Mohan, Tu, and Efange, 
2002; Walf, Rhodes, and Frye, 2006).     
Training: Two identical sphere-shaped objects were placed into adjacent corners of the 
open field chamber.  Rats were placed in a corner opposite the objects.  Rats were 
allowed to freely explore the chamber for 3 minutes, and time spent interacting with each 
object was recorded.  The rats were then single housed.   
Testing: Four hours later, rats were placed back into the same chamber for another 3 
minutes with one of the objects having been replaced with a novel cone-shaped object.  
Amount of time spent interacting with each object was recorded. Greater percentage of 
time spent with the novel, compared to the familiar, object was used as an indication of 
enhanced working memory.   
Object Placement: Methods were as previously described (Ennaceur & Delacour 1988; 
Frye, Duffy, and Walf, 2007; Frye & Lacey, 2001; Luine et al., 2003; Paris & Frye, 
2008). Training was the same as for object recognition and testing involved the same 
objects with one moved to the corner opposite its starting position.  The amount of time 
spent with each object was recorded.  Greater percentage of time spent with the object in 
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the novel/displaced location, compared to the object in the familiar location, was used as 
an indication of enhanced spatial cognition.   
Morris Water Maze: This was conducted as described previously (Vongher & Frye 1999; 
Frye, Edinger, Lephart, and Walf, 2010).  
Habituation: On day one, rats were allowed to swim for 60 secs, in a large circular tank 
(175 cm. diameter, 71 cm deep), with water (24-26oC), that had white, non-toxic, tempera 
paint added to make it opaque.   
Training: On day two, a clear Plexiglas platform, with a top that measures 5.3cm x 
5.3cm, was placed in one of the four quadrants 30 cm from the side of the pool.  The 
water level was filled so that it was 2.5cm above the top of the hidden platform.  Rats 
were given two minutes to find the platform during two trials.  Each trial was initiated 
from a different quadrant. If the rat did not reach the platform within 120 secs, it was 
guided to it and remained on the platform for 45 secs.   
Testing: On day three, rats were allotted 120 secs to find the platform during each of four 
trials.  Each trial was initiated from a different quadrant. The latency to find the hidden 
platform and the distance traveled were recorded.  Shorter latencies and distances are 
considered indicative of better spatial performance.   
Open Field: This was conducted per previous methods (Frye et al., 2000; McCarthy, 
Felzenberg, Robbins, Pfaff, and Schwartz-Giblin, 1995). A grid of 48 squares (9.5 cm 
width each) was superimposed on the floor of the test chamber by the video-tracking 
system.  Entries into outer squares (those adjacent to the outer wall; n=24), central 
squares (all other squares apart from the outer; n=24), are recorded.  The number of 
central square entries is used as an index of anti-anxiety-like behavior. 
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Light-Dark Transition: This task was conducted per previously described methods (Walf 
& Frye, 2005). Rats were placed on the light side of a two-chambered compartment (30 
X 40 X 40 cm), which has white walls and floor, and is illuminated from above by a 40-
watt light. The opposing side of the chamber is black and has a lid. The number of entries 
between the light and dark side of the chamber was recorded for 5 mins.  An entry into 
the light side of the chamber is considered an indication of anti-anxiety behavior. 
Mirror Maze: As per previous methods (Frye et al., 2006), the testing chamber is 52 x 57 
x 52 cm.  It has within it, a mirrored-compartment (52 x 5 x 52 cm) and an alleyway 
without mirrors.  Rats are placed in the alley section, and the number of entries to the 
mirrored chamber were recorded. More entries to the mirror chamber is an indication of 
anti-anxiety behavior.   
Tissue Collection 
 Immediately following testing, subjects were terminated by rapid decapitation. 
Trunk blood was collected and centrifuged (10 mins at 3000 x g).  Brain and prostates 
were extracted, weighed, and flash frozen on dry ice. Brain, prostates, and plasma were 
stored at -80C. Before radioimmunoassay, hypothalamus, hippocampus, frontal cortex, 
and midbrain, were grossly dissected on ice as previously described (Frye, Paris, and 
Rhodes, 2007).  
Radioimmunoassay 
 T, DHT, and E2 concentrations were assessed by radioimmunoassay as previously 
described (Edinger Lee and Frye, 2004; Frye & Bayon, 1999; Frye, McCormick, 
Coopersmith, and Erskine, 1996).  Briefly, the T antibody (T3-125; Endocrine Sciences, 
Calabasas Hills, CA) was diluted 1:20, 000 and binds between 60% and 65% of [3H] T 
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(NET-387: specific activity = 51.0 ci/mmol). The DHT antibody (DT3-351; Endocrine 
Sciences) was diluted 1:10,000 and binds between 60% and 65% of [3H] DHT (NET-302: 
specific activity = 43.5 ci/mmol). The E2 antibody (Dr. Niswender, #244, Colorado State 
University, Fort Collins, CO) was diluted 1:30, 000 and binds approximately 90% of [3H] 
E2 (NET-317: specific activity = 51.3 ci/mmol). Standard curves for all steroids were run 
in duplicate and ranged from 50 - 2000 pg in concentration. Standards were added to 
BSA assay buffer, followed by addition of the appropriate antibody and [3H] steroid. The 
T and DHT assays were incubated overnight at 4C.  The E2 radioimmunoassay was 
incubated at room temperature for 50 min. Separation of bound and free steroid was 
accomplished by the rapid addition of dextran-coated charcoal. Samples were centrifuged 
at 3000 X g for 10 min, following incubation with charcoal. Supernatant was decanted 
into 5 ml scintillation cocktail. The intra- and interassay coefficients of variance were: T 
= 0.09 and 0.04, DHT = 0.08 and 0.09, E2 = 0.09 and 0.09.   
5-reductase activity 
As per previously methods (Kellogg & Frye 1999), the turnover ratios of T to 
DHT were calculated and used as an index of 5-reductase activity. 
Statistical Analyses 
Three-way analyses of variance (ANOVAs) with between-subjects factors of, 
gonadal status (intact, GDX), T condition (T-containing or empty silastics), and enzyme 
inhibitor (vehicle, 5-reductase inhibitor, finasteride or aromatase inhibitor, formestane) 
were utilized for each measure examined. Interactions were assessed via one-way follow-
up ANOVAs with alpha level conditions corrected for multiple comparisons. Where 
appropriate, Fisher’s protected least significant differences post-hoc tests were utilized to 
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determine group differences. Simple regressions were used to assess the amount of 
variance that could be explained for each behavior by 5-reductase activity in the 
hippocampus. The alpha level for statistical significance was p < 0.05. Trends towards 
significance are noted when p < 0.10. A few samples ( < 10), were lost during 
radioimmunoassay causing slight variation in degrees of freedom. 
Results  
Procedure 
  Gonadally-intact and gonadectomized rats with silastic implants that were empty 
or containined T (Edinger & Frye 2006) had effects of 5-reductase and aromatase 
enzyme inhibitors examined in Experiments 1 and 2, respectively.  Sexual, social, 
cognitive, and anxiety behaviors were examined.  Following completion of the testing 
battery, prostate, plasma and brains were collected for endocrine analyses   
Experiment 1: The importance of T’s 5-reduced metabolites was examined with 
a 5-reductase inhibitor, finasteride (Steraloids, Newport, RI).  Finasteride blocks both 
type I and type II isoforms of the 5-reductase enzyme, such that it can decrease 
metabolism of T by ~75% (Finn et al., 2006; Rittmaster, 1994; McConnell & Stoner, 
2001).  There were eight experimental groups: intact rats implanted with finasteride 
(n=20), intact rats implanted with control silastics (n=20), intact rats implanted with T 
(n=15), intact rats implanted with T and finasteride (n=15), GDX rats implanted with T 
(n=16), GDX rats implanted with finasteride (n=15), GDX rats implanted with both T 
and finasteride (n=17), and GDX rats implanted with control/empty silastics (n=14).   
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Experiment 2: The importance of T’s aromatized, metabolites was examined with 
an aromatase inhibitor, formestane (Sigma, St. Louis, MO).  Formestane is a selective 
steroidal aromatase inhibitor, such that it can decrease E2 levels in circulation and brain 
(Martínez-Mota et al., 2008; Lenning et al., 2001).  For Experiment 2, there were eight 
treatment groups: intact rats implanted with formestane (n=16), intact rats implanted with 
control silastics (n=18), intact rats implanted with T and formestane (n=15), intact rats 
implanted with T (n=15), GDX rats implanted with T (n=15), GDX rats implanted with 
formestane (n=13), GDX rats implanted with both T and formestane (n=13), and GDX 
rats implanted with control silastics (n=13).   
Experiment 1 
GDX decreased  levels of T and DHT, while increasing E2 levels. 
There were significant main effects of GDX to decrease T and DHT levels in 
plasma [T: F(1,123) = 335.28, p < 0.05; DHT: F(1,123) = 77.67, p < 0.05], hypothalamus 
[T: F(1,124) = 13.36, p < 0.05; DHT F(1,123) = 7.54, p < 0.05], hippocampus [T: 
F(1,123) = 20.37, p < 0.05; DHT F(1,123) = 34.80, p < 0.05], cortex [T: F(1,122) = 
18.19, p < 0.05; DHT: F(1,123) = 12.60, p < 0.05], and midbrain [T: F(1,122) = 33.61, p 
< 0.05; DHT: F(1,122) = 51.86, p < 0.05]. GDX increased E2 levels in plasma [F(1,123) 
= 58.01, p < 0.05], hypothalamus [F(1,123) = 7.45, p < 0.05], and midbrain 
[F(1,121)=13.92, p < 0.05].  See table I. 
T administration increased levels of, T and DHT E2 
T implants increased T levels significantly in plasma [F(1,123) = 14.15, p < 0.05] 
and tended to increase T levels in the cortex [F(1,122) = 2.88, p < 0.10.  T implants 
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significantly increased DHT levels in the midbrain [F(1,122) = 5.270, p < 0.05]. T 
implants decreased E2 levels in plasma [F(1,123) = 16.664, p < 0.05] and increased levels 
of E2  in the hippocampus [F(1,122) = 5.338, p < 0.05].  See table I.   
5-reductase turnover, as indicated by T to DHT ratios, are in table I (bottom). 
GDX and/or Finasteride Decreased Prostate Weight, Sex, and Social Behavior  
 Prostate weight was significantly decreased by GDX [F(2,124) = 36.97, p < 0.05] 
and finasteride  [F(1,124) = 18.37, p < 0.05] and increased by T [F(1,124) = 11.71, p < 
0.05]  (Figure 1; top panel).   
 Latencies to initial intromission were significantly increased by GDX [F(1,124) = 
77.07, p < 0.05] and finasteride  [F(1,124) = 4.129, p < 0.05] (Figure 1; middle). 
 The duration of time spent in social interaction with a conspecific was decreased 
by GDX [F(1,124) = 77.07, p < 0.05] (Figure 1; bottom).   
T improved working memory, GDX or Finasteride Decreased Spatial Performance 
 In the object recognition task, rats with T-containing compared to empty silastic 
implants spent significantly more time with the novel object [F(1,124) = 3.87, p = 0.05], 
an indication of better working memory (Figure 2; top).   
In the object placement task, GDX compared to intact rats spent significantly less 
time with the displaced object [F(1,124) = 5.14, p < 0.05], a measure of poorer spatial 
memory (Figure 2; middle).   
In the Morris Water Maze, finasteride-administered rats tended to have longer 
latencies to find the hidden platform [F(1,124) = 2.80, p < 0.10], a measure of poorer 
spatial memory (Figure 2; bottom).   
GDX Produced Anxiety-Like Behavior in the Light/Dark and Mirror Mazes 
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In the light/dark transition task, GDX rats made fewer entries into the light 
chamber [F(1,124) = 17.85, p < 0.05], an indication of anxiety-like behavior (Figure 3; 
middle).  
In the mirror maze, GDX rats spent less time in the mirrored chamber [F(1,124) = 
23.223, p < 0.05], indicative of anxiety-like behavior  (Figure 3; bottom).  
No differences were seen in the open field task (Figure 3; top). 
5a-reduction in the Hippocampus Accounts for Variable Effects in Behavior 
Simple regressions revealed the 26% of the variance could be explained for all 
behaviors examined in total by 5-reductase activity in the hippocampus (table II, left). 
Results Experiment 2 
GDX decreased  levels of T and DHT, while increasing E2 levels. 
GDX decreased T and DHT levels in plasma [T: F(1,112) = 176.46, p < 0.05;  
DHT  [F(1,112) = 9.619, p < 0.05], hypothalamus [T: [F(1,112) = 17.10, p < 0.05];  DHT 
[F(1,112) = 63.454, p < 0.05], hippocampus [T: [F(1,112) = 65.47, p < 0.05]; DHT 
[F(1,112) = 35.66, p < 0.05], cortex [T: [F(1,112) = 44.38, p < 0.05]; DHT: [F(1,112) = 
57.70, p < 0.05], and midbrain [T: [F(1,112) = 3.95, p < 0.05]; DHT: [F(1,112) = 51.01, 
p < 0.05]. GDX increased E2 levels in the hippocampus [F(1,112) = 11.25, p < 0.05] and 
midbrain [F(1,112) = 9.93, p < 0.05] (table III). 
T administration increased levels of T and decreased levels of DHT. 
T implants increased T levels significantly in hippocampus [F(1,112) = 4.97, p < 
0.05] and decreased DHT levels in plasma [F(1,112) = 7.377, p < 0.05] See table III.   
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Formestane tended to increase central levels of T. 
 Formestane tended to increase T levels in the hippocampus [F(1,112)=3.50], p < 
0.1] (table III). 
GDX Decreased Prostate Weight, Sex, and Social Behavior  
 Prostate weight was significantly decreased by GDX [F(1,111) = 369.43, p < 
0.05] and increased by T administration [F(1,111) = 11.593, p < 0.05]  (Figure 4; top).   
 Latencies to initial intromission were significantly increased by GDX  [F(1,112) = 
11.916, p < 0.05] (Figure 4; middle). 
 The duration of time spent in social interaction with a conspecific was decreased 
by GDX [F(1,112) = 12.823, p < 0.05] (Figure 4; bottom).   
Formestane improved working memory and GDX Decreased Spatial Performance 
 In the object recognition task, formestane increased time spent with the novel 
object [F(1,112) = 5.72, p < 0.05], indicating better cognitive performance (Figure 5; 
top).   
In the Morris Water Maze, GDX tended to increase latencies to the hidden 
platform [F(1,112) = 3.14, p < 0.10], suggesting poorer spatial memory (Figure 5; 
bottom).   
No differences were seen in the object placement task (Figure 5; middle) 
 Formestane increased, and GDX decreased, anti-anxiety like behavior 
In the open field task, formestane tended to increase the number of central entries 
[F(1,112) = 3.09, p < 0.10], indicating more anti-anxiety-like behavior (Figure 6, top).   
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In the light/dark transition task, GDX rats made fewer entries into the light 
chamber [F(1,112) = 31.67, p < 0.05], an indication of anxiety-like behavior (Figure 6; 
middle).  
In the mirror maze, GDX rats spent less time in the mirrored chamber [F(1,112) = 
46.5, p < 0.05], indicative of anxiety-like behavior  (Figure 6; bottom).  
5a-reduction in the Hippocampus Accounts for Variable Effects in Behavior 
Simple regressions revealed the 36% of the variance could be explained by 5-
reductase activity in the hippocampus (table II, right). 
 
Conclusions 
These findings partly supported our hypothesis that T’s 5α-reduction mediates 
some of its behavioral and peripheral effects.  We found that reducing androgens via 
GDX decreased prostate weight, sexual interest in the standard mating paradigm, 
cognitive performance in the object placement task, and anti-anxiety-like behavior in 
social interaction, light-dark transition, and mirror maze tasks. Systemic administration of 
T significantly increased prostate weight, and enhanced cognition in the object 
recognition task. Blocking T’s metabolism to its 5-reduced metabolites via systemic 
finasteride administration significantly decreased prostate weight, and increased latencies 
to sexual behavior supporting a role for trophic effects of 5-reduced androgens. In 
addition, there were tendencies for finasteride to reduce cognitive performance in the 
water maze task.  Blocking T’s metabolism to E2, via systemic formestane 
administration, did not significantly alter prostate mass or sexual behavior, but it did 
improve cognition in the object recognition task, and tended to decrease anxiety-like 
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behavior in the open field task.  As such, these data support a role for gonadal status in 
sexual, affective, and cognitive behavior, and suggest that centrally routing T’s 
metabolism toward 5α-reduction improves behaviors.   
 Castration reduced prostate proliferation while producing negative effects on 
behavior.  As hypothesized, GDX significantly decreased prostate weight, consistent with 
past studies (Brooks Primka, Berman, Krupa, Reynolds, and Rasmusson, 1991; Borst et 
al., 2007), and this was associated with lower levels of DHT and T in plasma.  Notably E2 
levels remained the same or were increased with GDX. We observed a decrease in sexual 
motivation in the present study similar to that of prior investigations (McGinnis, Mirth, 
Zebrowski, and Dreifuss, 1989; Hull & Dominguez, 2007; Davidson 1966).  One 
structure that may be particularly important in this effect is the midbrain which is thought 
to mediate sexual behavior of rodents (Murphy, Rizvi, Ennis, and Shipley, 1999; Brackett 
& Edwards, 1984). Herein, we find that reduced androgen formation in the midbrain 
correlated with decreased sexual motivation. Indeed, decreases in androgen formation 
with GDX were also observed in hippocampus and cortex, regions that are critical for 
cognitive and anxiety-like behavior. (Aubele et al., 2008; Sandstrom, Kim, and 
Wasserman, 2006; Kritzer, McLaughlin, Smirls, and Robinson, 2001). In the present 
study, GDX decreased cognitive performance, which has been associated with androgen 
milieu in cortex and hippocampus (Kaut & Bunsey, 2001; Brown, Wilson, and Riches, 
1987). Notably, androgens in the cortex and hippocampus are implicated in anxiety-like 
behaviors (Bannerman, Deacon, Offen, Friswell, Grubb, and Rawlins, 2002; Frye & 
Edinger 2004). In the present investigation, GDX increased anxiety-like behavior in the 
light/dark maze, mirror maze, and social interaction tasks supporting past findings of 
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GDX to increase anxiety-like behavior in rodents (Edinger & Frye; 2004, Bitran, 
Kellogg, and Hilvers, 1993; Frye & Seliga, 2001, Fernández-Guasti & Martínez-Mota, 
2003; Adler et al., 1999), and reductions in these behaviors correlated with decreases in 
androgens in hippocampus and cortex. Thus, GDX decreased androgen levels, prostate 
weight, sexual performance, anti-anxiety behavior, and spatial cognition. 
 Administration of T increased prostate proliferation while improving cognitive 
behavior.  Others have demonstrated that prostate mass is increased with T administration 
(Borst et al., 2008). We found that prostate mass correlates with increased levels of DHT 
and T found in plasma, indicating an important role for ARs in these effects. Androgens 
are often utilized to treat sequelae of aging, including decreased libido. While past studies 
have found that systemic T administration can reinstate sexual behavior commensurate to 
levels akin to gonadally-intact rats (McGinnis et al., 1989), we did not observe this 
enhancement. This may be due to the fact that our hormone regimen aimed to produce 
low physiological levels of T and its 5-reduced metabolites in brain (Edinger & Frye, 
2004), whereas others that have demonstrated sexual enhancement via T replacement to 
GDX rats have utilized regimen that are approximately twice what was used in the 
present study (McGinnis et al.). As such, even low levels of androgen reinstatement that 
do not readily produce expected behavioral enhancement may be relevant for prolific 
effects on prostate. Notably, it is rare to observe sexual behavior among GDX rats that 
did not have sexual experience prior to GDX, as was the case in this investigation 
(Retana-Marquez & Velazquez-Moctezuma, 1997) which likely contributed to the 
observed lack of sex effects in our model.  Contrary to our hypothesis, administration of 
T did not have any effects on anxiety-like behavior.  This dosage of T, 10mm silastic 
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implant, has been shown to not alter behavior in the open field and social interaction 
tasks (Frye & Seliga, 2001), which may be due to this regimen only producing low 
physiological levels of T and its 5-reduced metabolites in brain (Edinger & Frye, 2004).  
Thus, we found clear effects of T-replacement to increase prostate mass and improve 
cognitive performance. 
Finasteride decreased prostate proliferation and decreased sexual behavior, 
whereas formestane enhanced cognition without altering prostate weight.  Finasteride, 
decreased prostate weight, as it has been shown to do in past studies (Borst et al., 2008); 
yet, formestane administration did not have any effect on prostate.  Of interest, finasteride 
administration decreased sexual motivation in the standard mating paradigm, supporting 
past findings wherein administration of T’s 5α-reduced metabolites have been shown to 
increase mounting behavior (Butera & Czaja, 1989). Men have also shown slightly 
decreased sex drive with finasteride administration, which were reversed when treatment 
was ceased (Amory et al., 2008).  Formestane administration did not produce any 
significant effects on sexual behavior; however, formestane significantly increased time 
spent with an object in a novel location in the object recognition task. These beneficial 
effects observed with formestane administration may be due to its tendency to increase T 
produced by the hippocampus.   Finasteride’s effects on cognition tended to support this 
hypothesis in that there was a trend for increased latencies to find the hidden platform in 
the water maze task indicating poorer cognitive performance.  We have previously 
observed T’s 5α-reduced metabolites to increase cognition (Frye, Koonce, Edinger, 
Osbourne, and Walf, 2008).   These findings suggest that the presence and importance of 
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androgens in the prostate, the putative effects of DHT’s actions at these targets, and the 
effectiveness of finasteride in reducing prostate proliferation.   
 It important to understand the extent to which T’s 5-reduced, versus aromatized 
metabolites, mediate trophic effects in the brain and periphery, as these androgens can 
have different targets.  While both T and DHT bind with high affinity to intracellular 
ARs, DHT binds with a higher affinity than does T (Roselli, Horton, and Resko, 1987).  
Among GDX rats, administration of DHT produces similar effects to administration of T, 
for reinstatement of cognitive, affective, and depressive performance to levels akin to 
those observed among intact rats (Edinger and Frye, 2005; Frye et al., 2004; Edinger and 
Frye, 2004; Frye & Walf, 2009).  However, DHT is highly active in prostate where it 
may cause harmful proliferation (Tindall & Rittmaster, 2008).  As such, some of the 
prostatic trophic effects of T’s metabolites may outweigh their beneficial actions for 
sexual behavior, affect, and cognition.  Because of the importance of DHT in prostate 
proliferation, 5α-reductase inhibitors have been used as a treatment for BPH and prostate 
cancer (Marks et al., 1999, Fleshner, Trachtenberg, Walsh, and Crawford, 1995; Brufsky, 
1997).  Finasteride’s inhibition of T’s 5α-reduction, and formestane’s inhibition of 
aromatase, may alter actions at intra-cellular receptors (ARs and ERs), as well as at 
membrane receptors, due altered levels of DHT and E2.  In addition, past findings have 
demonstrated the importance of actions at these receptors, and other targets, in the brain 
in the mediation of cognitive, anxiety-like, and sexual behavior (Naghdi, Nafisy, and 
Majlessi, 2001; Frye et al., 2008; Edinger &  Frye, 2006; Weiser, Foradori, and Handa 
2008; Phillips-Farfán, Lemus, and Fernandez-Guasti, 2007).  Of interest in future 
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investigations is the relative roles of T and its metabolites at these receptor targets in the 
brain and peripheral, androgen-sensitive tissues, such as the prostate.  
In conclusion, these results suggest that some of T's behavioral and trophic effects 
may be mediated largely through its metabolites, and that shifting T’s metabolism 
towards 5α-reduction can improve behaviors. This is supported by correlations seen 
between varying levels of these metabolites in the brain and behavior, and correlations 
between the reduction in prostate weight and the levels of these metabolites in plasma.  
This also suggests finasteride to be useful for treating BPH, and prostate cancer, because 
it produced much more salient effects on the prostate than on behavior, and it did not 
alter hormone levels in any brain regions.   Concerning formestane, these results suggest 
that reducing aromatization may be beneficial because it produces positive effects on 
behavior without negative effects on the periphery.  Formestane improved cognition, and 
tended to decrease anxiety like behavior.  While TRT also improves behaviors, it 
produces negative effects on the prostate, which we did not see with formestane 
administration, suggesting the utility of formestane co-administration with androgen 
therapies.  Castration-resistant prostate cancer, a leading cause of death among men, 
underscores the importance of understanding androgen actions and receptor mechanisms, 
as such cancers typically progress despite low levels of T (Mostaghel, Montgomery and 
Nelson, 2009).   
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Figure Legends- Experiment 1 
Figure 1: Depicts the average prostate weight (SEM) and represents the sociosexual 
data.  This includes the latency ( SEM) to intromission for the sex testing and the mean 
interaction time ( SEM) for the Social Interaction task for gonadectomized (GDX) or 
intact male rats (n=14-20/group) implanted with vehicle, finasteride, and/or testosterone. 
* indicates main effect of gonadal condition, p < 0.05, ^ indicates main effect of T 
condition, p < 0.05, # indicates main effect of inhibitor condition, p < 0.05. 
 
 
Figure 2: Represents the cognitive data.  This includes the percentage of time ( SEM) 
for the Object Recognition and Object Placement tasks and the mean average ( SEM) 
latency to the hidden platform in the Morris Water Maze. * indicates main effect of 
gonadal condition, p < 0.05, ^ indicates main effect of T condition, p < 0.05, ## indicates 
a tendency for main effect of inhibitor condition, p < 0.05. 
 
Figure 3 Represents the anxiety data.  This includes the mean central entries ( SEM) for 
the Open Field task, the mean white chamber entries ( SEM) for the Light/Dark 
Transition task, and the mean time spent in the mirror chamber ( SEM) for the Mirror 
Maze task.  * indicates main effect of gonadal condition, p < 0.05. 
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Table I: Concentrations of testosterone, dihydrotestosterone, and estradiol in midbrain, hypothalamus, cortex, hippocampus, 
interbrain, and plasma, of gonadectomized (GDX) or intact male rats (n=14-20/group) implanted with vehicle, finasteride, and/or 
testosterone (mean±SEM). * indicates main effect of gonadal condition, p < 0.05, ^ indicates main effect of T condition, p < 0.05, ^^ 
indicates tendency for a main effect of T condition, p < 0.1 
Gonad GDX Intact 
Gonadal 
Condition 
T 
Condition 
T Vehicle Testosterone Vehicle Testosterone     
Inhibitor Veh Fin veh Fin veh Fin veh Fin     
T Levels       
Plasma 28.128 28.447 32.377 33.609 43.865 40.717 41.13 43.525 *   
± Std error 0.56 0.255 0.51 0.676 1.263 0.884 0.772 1.272     
Hypothalamus 3.966 3.977 3.958 4.09 4.46 4.322 4.26 4.373 *   
± Std error 0.163 0.099 0.105 0.053 0.122 0.059 0.253 0.161     
Hippocampus 1.633 1.593 1.641 1.744 1.806 1.844 1.703 1.833 *   
± Std error 0.028 0.035 0.024 0.042 0.041 0.04 0.078 0.062     
Cortex 1.545 1.646 1.637 1.692 1.866 1.752 2.106 1.806 * ^^ 
± Std error 0.03 0.026 0.034 0.034 0.032 0.026 0.236 0.04     
Midbrain 1.914 1.957 2.051 2.079 2.326 2.228 2.347 2.275 *   
± Std error 0.048 0.044 0.05 0.091 0.063 0.034 0.119 0.091     
DHT Levels       
Plasma 150.68 133.937 308.286 301.875 849.76 710.651 450.821 547.135 *   
± Std error 9.63 15.756 47.769 32.898 119.591 59.446 44.865 58.194     
Hypothalamus 95.086 46.365 56.34 39.919 90.757 107.877 100.787 91.857 *   
± Std error 41.424 14.486 18.786 3.905 18.01 22.705 24.1 12.263     
Hippocampus 21.775 30.598 20.642 33.068 67.674 62.954 66.648 71.315 *   
± Std error 6.778 11.006 4.203 9.915 8.815 13.669 4.834 6.4     
Cortex 29.345 16.955 30.453 26.459 45.703 49.792 48.646 42.583 *   
± Std error 10.17 5.116 11.019 5.445 6.16 9.46 5.364 4.009     
Midbrain 14.565 14.427 20.243 40.14 63.25 51.039 66.464 65.021 * ^ 
± Std error 3.407 2.746 3.232 13.297 9.613 6.328 5.622 5.468     
E2 Levels       
Plasma 17.913 17.153 17.357 17.391 16.175 16.306 14.063 13.632 * ^ 
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± Std error 0.33 0.369 0.317 0.287 0.671 0.269 0.578 0.464     
Hypothalamus 2.507 2.694 2.584 2.712 2.206 2.146 2.102 2.503 * ^ 
± Std error 0.128 0.189 0.145 0.111 0.128 0.102 0.162 0.431     
Hippocampus 1.025 1.034 1.058 1.124 0.941 0.888 0.989 1.302     
± Std error 0.05 0.04 0.047 0.049 0.043 0.04 0.083 0.223     
Cortex 1.001 1.012 1.026 1.118 0.888 0.826 1.075 0.972     
± Std error 0.059 0.06 0.054 0.053 0.046 0.034 0.227 0.192     
Midbrain 1.286 1.347 1.357 1.337 1.116 1.071 0.97 1.212 *   
± Std error 0.084 0.072 0.087 0.088 0.055 0.061 0.08 0.166     
5α-reductase 
activity   
Hypothalamus 19.909 11.874 14.645 9.774 19.745 24.247 22.341 20.477     
Hippocampus 13.018 18.281 12.547 22.523 37.546 32.414 39.855 38.696     
Cortex 18.359 10.104 17.923 15.851 24.227 28.349 23.364 23.466     
Midbrain 7.882 7.274 9.611 18.344 26.527 22.508 28.17 28.578     
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Table II:  Simple regressions for all behaviors examined in total by 5-reductase activity in the hippocampus for GDX or intact male 
rats (n=14-20/group) implanted with vehicle, finasteride, and/or testosterone (left), and GDX or intact male rats (n=13-18/group) 
implanted with vehicle, formestane, and/or testosterone. 
Finasteride-
Task vs. 
hippocampal T 
5 Reduction 
R 
Squared 
Regression 
P-Value  
Formestane-
Task vs. 
hippocampal T 
5 Reduction 
R 
Squared 
Regression 
P-Value 
Lat to Intro 0.075 0.0015  Lat to Intro 0.226 <0.0001 
Central entries 0.006 0.3824  Central entries 0.003 0.5287 
Interaction Time 0.014 0.1812  Interaction Time 0.094 0.0007 
Mirror Entries 0.071 0.002  Mirror Entries 0.005 0.442 
White Entries 0.029 0.053  White Entries 0.021 0.1116 
Obj Rec % Novel 0.042 0.019  Obj Rec % Novel 0.009 0.311 
Obj Place % Novel 0.025 0.0736  Obj Place % Novel 
9.83E-
05 0.9148 
H20 Avg Lat 0.001 0.6782  H20 Avg Lat 0.001 0.7356 
FST Struggling 0.022 0.0833  FST Struggling 0.003 0.5287 
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Figure 2 
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Figure Legends- Experiment 2 
Figure 4: Depicts the average prostate weight (SEM) and represents the sociosexual 
data.  This includes the latency ( SEM) to intromission for the sex testing and the mean 
interaction time ( SEM) for the Social Interaction task for gonadectomized (GDX) or 
intact male rats (n=13-18/group) implanted with vehicle, formestane, and/or testosterone. 
* indicates main effect of gonadal condition, p < 0.05, ^ indicates main effect of T 
condition, p < 0.05. 
 
Figure 5: Represents the cognitive data.  This includes the percentage of time ( SEM) 
for the Object Recognition and Object Placement tasks and the mean average ( SEM) 
latency to the hidden platform in the Morris Water Maze. ** indicates a tendency for 
main effect of gonadal condition p < 0.10, # indicates a significant difference for the 
inhibitor condition p < 0.05. 
 
Figure 6 Represents the anxiety data.  This includes the mean central entries ( SEM) for 
the Open Field task, the mean white chamber entries ( SEM) for the Light/Dark 
Transition task, and the mean time spent in the mirror chamber ( SEM) for the Mirror 
Maze task. * indicates main effect of gonadal condition, p < 0.05 ## indicates a tendency 
for main effect of the inhibitor condition. 
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Table III: Concentrations of testosterone, dihydrotestosterone, and estradiol in midbrain, hypothalamus, cortex, hippocampus, 
interbrain, and plasma of gonadectomized (GDX) or intact male rats (n=13-18/group) implanted with vehicle, formestane, and/or 
testosterone (mean±SEM). * indicates main effect of gonadal condition, p < 0.05, ^ indicates main effect of T condition, p < 0.05, ^^ 
indicates tendency for a main effect of T condition, p < 0.1, and ## indicates tendency for a main effect of inhibitor condition, p < 0.1 
Gonad GDX Intact 
Gonadal 
Condition 
T 
Condition 
Inhibitor 
Condition 
T Vehicle Testosterone Vehicle Testosterone       
Inhibitor veh Form veh Form veh Form veh Form       
T Levels         
Plasma 25.661 25.787 29.267 30.19 45.213 46.837 42.453 40.365 *     
± Std error 0.669 0.328 0.685 0.498 2.406 3.091 1.433 0.622       
Hypothalamus 3.134 3.396 3.375 3.641 3.849 3.965 4.419 3.798 *     
± Std error 0.286 0.133 0.152 0.15 0.175 0.102 0.332 0.266       
Hippocampus 0.01 0.011 0.011 0.012 0.014 0.013 0.014 0.014 * ^ ## 
± Std error 0.001 3.90E-04 4.79E-04 4.15E-04 3.67E-04 3.24E-04 0.001 3.77E-04       
Cortex 0.01 0.011 0.011 0.012 0.013 0.013 0.012 0.012 *     
± Std error 3.41E-04 4.11E-04 2.89E-04 2.12E-04 3.19E-04 2.68E-04 4.13E-04 4.47E-04       
Midbrain 1.803 1.798 1.75 1.86 1.957 2.089 1.867 1.777 *     
± Std error 0.069 0.084 0.08 0.037 0.061 0.063 0.073 0.161       
DHT Levels         
Plasma 2139.227 1503.359 1681.376 1670.884 2846.934 2724.256 2072.533 1773.293 * ^   
± Std error 275.988 391.94 269.121 385.3 194.511 147.792 242.12 172.43       
Hypothalamus 34.91 25.899 35.966 37.89 178.756 207.481 225.274 167.426 *     
± Std error 2.531 4.543 3.398 4.615 38.025 47.473 67.229 16.138       
Hippocampus 14.602 14.715 16.861 21.959 48.494 69.982 37.45 40.313 *     
± Std error 1.826 1.651 2.677 4.561 9.08 14.903 3.027 6.333       
Cortex 14.791 11.768 14.071 19.82 57.538 75.165 53.107 59.006 *     
± Std error 1.907 1.687 1.959 3.856 11.392 16.074 4.803 7.236       
Midbrain 14.638 14.841 18.237 19.146 59.497 93.98 58.189 53.064 *     
± Std error 1.706 1.948 2.741 2.286 11.901 20.799 3.545 5.393       
E2 Levels         
Plasma 18.187 18.407 17.892 18.284 18.433 17.976 20.52 20.321       
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± Std error 0.282 0.376 0.387 0.33 0.55 0.283 1.256 1.559       
Hypothalamus 2.807 2.83 2.88 2.947 1.66 2.696 0.267 0.285       
± Std error 0.123 0.181 0.179 0.068 0.305 0.108 0.022 0.025   ^^   
Hippocampus 1.185 1.195 1.156 1.068 0.932 1.081 0.749 0.929 *     
± Std error 0.054 0.071 0.063 0.042 0.084 0.026 0.045 0.22       
Cortex 1.102 1.159 1.095 1.081 1.047 1.073 0.992 1.018 *     
± Std error 0.048 0.059 0.038 0.033 0.054 0.029 0.123 0.11       
Midbrain 1.382 1.468 1.422 1.414 1.213 1.304 1.263 1.099 *     
± Std error 0.065 0.097 0.054 0.05 0.101 0.06 0.109 0.136       
5α-reductase 
activity   
Hypothalamus 10.564 7.762 10.802 10.559 45.703 50.942 45.684 43.873       
Hippocampus 1506.632 1332.824 1569.924 1882.994 3547.376 5109.681 2719.581 2795.789       
Cortex 1460.975 1114.081 1251.234 1707.829 4542.731 5432.153 4281.126 4746.839       
Midbrain 8.252 8.165 10.699 10.308 31.217 45.189 31.829 30.728       
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Figure 4  
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Figure 5
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